Anika Therapeutics, Inc. (ANIK)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-20M 0 20M 40M 60M Q3 '21: 39.5M Q4 '21: 35.8M Q1 '22: 36.7M Q2 '22: 39.7M Q3 '22: 40.3M Q4 '22: -2.8M Q1 '23: 37.9M Q2 '23: 44.3M Q3 '23: 41.5M Q4 '23: -2.9M Q1 '24: 29M Q2 '24: 30.7M Q3 '24: 29.6M Q4 '24: 30.6M Q1 '25: 26.2M Q2 '25: 28.2M Q3 '25: 27.8M Q4 '25: 30.6M Q1 '26: 29.6M Q2 '26: 32.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 10M 20M 30M Q3 '21: 23M Q4 '21: 18.1M Q1 '22: 21.8M Q2 '22: 24.9M Q3 '22: 22.8M Q4 '22: 3.8M Q1 '23: 22.8M Q2 '23: 29M Q3 '23: 24.9M Q4 '23: 5.8M Q1 '24: 19M Q2 '24: 20.5M Q3 '24: 19.4M Q4 '24: 17.1M Q1 '25: 14.7M Q2 '25: 14.4M Q3 '25: 15.6M Q4 '25: 19.2M Q1 '26: 19M Q2 '26: 21.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-18M -9M 0 9M 18M 27M Q1 '21: 1.3M Q2 '21: 9.2M Q3 '21: 1.3M Q1 '22: -3.6M Q2 '22: -3.4M Q3 '22: -5.8M Q1 '23: -12.6M Q2 '23: -3.6M Q3 '23: -7.7M Q4 '23: 24.7M Q1 '24: -2.5M Q2 '24: -1.8M Q3 '24: -81K Q4 '24: -705K Q1 '25: -4.3M Q2 '25: -4.2M Q3 '25: -3.2M Q4 '25: 646K Q1 '26: -5.5M Q2 '26: 3M Q2 '21 Q2 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q2 '21: 6.5M Q3 '21: 558K Q1 '22: -2.9M Q2 '22: -2.8M Q3 '22: -4.2M Q4 '22: -4.9M Q1 '23: -10.3M Q2 '23: -2.7M Q3 '23: -6.6M Q4 '23: -63M Q1 '24: -4.5M Q2 '24: -88K Q3 '24: -29.9M Q4 '24: -21.9M Q1 '25: -4.9M Q2 '25: -4M Q3 '25: -2.3M Q4 '25: 292K Q1 '26: -5.1M Q2 '26: 3.3M Q3 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 7M 14M 21M Q1 '21: 13.3M Q2 '21: 17.3M Q3 '21: 16.5M Q4 '21: 17.7M Q1 '22: 14.9M Q2 '22: 14.8M Q3 '22: 17.5M Q1 '23: 15.1M Q2 '23: 15.3M Q3 '23: 16.5M Q1 '24: 10M Q2 '24: 10.2M Q3 '24: 10.2M Q4 '24: 13.5M Q1 '25: 11.5M Q2 '25: 13.9M Q3 '25: 12.2M Q4 '25: 11.4M Q1 '26: 10.6M Q2 '26: 11.4M Q2 '21 Q1 '22 Q1 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '21: 2.1M Q4 '21: 4.5M Q1 '22: -1.9M Q2 '22: 3.1M Q3 '22: 2.7M Q4 '22: 481K Q1 '23: -3.6M Q2 '23: -8.3M Q3 '23: 6.5M Q4 '23: 3.6M Q1 '24: -126K Q2 '24: -1.1M Q3 '24: 5M Q4 '24: 1.6M Q1 '25: -130K Q2 '25: -189K Q3 '25: 6.9M Q4 '25: 4.6M Q1 '26: -4.8M Q2 '26: -684K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '21: 778K Q4 '21: 3.3M Q1 '22: -3.2M Q2 '22: 1.1M Q3 '22: 1M Q4 '22: -2M Q1 '23: -5M Q2 '23: -9.8M Q3 '23: 5.7M Q4 '23: 1.8M Q1 '24: -1.9M Q2 '24: -4.5M Q3 '24: 3.8M Q4 '24: 275K Q1 '25: -3M Q2 '25: -1.7M Q3 '25: 5M Q4 '25: 4M Q1 '26: -6.3M Q2 '26: -2.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q2 '20: 14.2M Q3 '20: 14.2M Q4 '20: 14.3M Q1 '21: 14.4M Q2 '21: 14.6M Q3 '21: 14.6M Q1 '22: 14.5M Q2 '22: 14.6M Q3 '22: 14.6M Q1 '23: 14.7M Q2 '23: 14.7M Q3 '23: 14.6M Q1 '24: 14.7M Q2 '24: 14.9M Q3 '24: 14.8M Q1 '25: 14.3M Q2 '25: 14.5M Q3 '25: 14.4M Q1 '26: 13.5M Q2 '26: 13.7M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '20: -0.31 Q4 '20: -1.69 Q1 '21: -1.89 Q2 '21: -0.90 Q3 '21: -0.41 Q4 '22: -1.03 Q1 '23: -1.54 Q2 '23: -1.53 Q3 '23: -1.69 Q4 '23: -5.65 Q1 '24: -5.25 Q2 '24: -5.06 Q3 '24: -6.64 Q4 '24: -3.83 Q1 '25: -3.86 Q2 '25: -4.14 Q3 '25: -2.27 Q4 '25: -0.76 Q1 '26: -0.79 Q2 '26: -0.27 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.